ST PETER PORT, GUERNSEY / ACCESSWIRE / October 3, 2022 / Goodbody Health Limited (AQSE:GDBY)(OTCQB:GDBYF) ('Goodbody' or the 'Company'), today announces that that it has signed a contract with Tasso Inc ('Tasso'), the leading provider of convenient, clinical grade blood collection solutions, for the UK pharmacy and wellness market. Tasso produces a signature line of virtually painless medical devices to draw a capillary blood sample with no needles and without the need for a phlebotomist, which can then be shipped to an accredited laboratory for analysis using a compatible sample collection reservoir. This will allow more Goodbody Health clinics and wellness locations as well as other healthcare professionals to undertake the tests requiring more blood than is delivered through the finger prick method.
This is great news for Goodbody Health customers, who will soon have a larger range of patient-friendly options available from their local Goodbody Clinic to check on their health. Goodbody expects to be rolling the devices out through its growing network of pharmacies in the UK later this year. This is one of the many ways that Goodbody is planning to use the latest technology to bring the very best options to its customers.
To supplement our in-clinic services, we have also expanded our range of ‘at home' test kits offered on stands supplied though a range of outlets. We are pleased to have achieved our first 100 stands offering options for those who prefer to test in the comfort of their own home.
Marc Howells, Chief Executive Officer, says; 'This is one of the biggest breakthroughs in the industry for a long time, allowing more pharmacists to offer the best test for each customer so they can ‘Know More - Live Better' '
The directors of the Company accept responsibility for the contents of this announcement.
On behalf of the Board of Directors,
Cautionary Statement Regarding Forward-Looking Statements
Neither the Canadian Securities Exchange nor its Market Regulator (as defined in the policies of the Canadian Securities Exchange) accept responsibility for the adequacy or accuracy of this release. This news release contains certain 'forward-looking information' within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute 'forward-looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Goodbody Health's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as 'plans', 'expects' or 'does not expect', 'is expected', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates' or 'does not anticipate', or 'believes' 'plan is' or variations of such words and phrases or may contain statements that certain actions, events or results 'may', 'could', 'would', 'might' or 'will be taken', 'will continue', 'will occur', 'will be achieved' or 'shortly'. The forward-looking information and forward-looking statements contained herein include, but are not limited to: the Tasso device will allow more Goodbody Health clinics and wellness locations as well as other healthcare professionals to undertake the tests requiring more blood than is delivered through the finger prick method; customers will soon have a larger range of patient-friendly options available from their local Goodbody Clinic to check on their health; Goodbody expects to be rolling the devices out through its growing network of pharmacies in the UK later this year.
Although Goodbody Health believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. In particular, there is no guarantee that; this is great news for Goodbody Health customers or that this is one of the biggest breakthroughs in the industry for a long time.
Goodbody Health does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws
SOURCE: Goodbody Health Limited
View source version on accesswire.com: